Skip to main content
. 2018 Dec 18;2018(12):CD006202. doi: 10.1002/14651858.CD006202.pub2

Biesbrock 2004.

Methods Title: a chewing gum containing 7.5% sodium hexametaphosphate inhibits stain deposition compared with a placebo chewing gum
Trial design: cross‐over randomised controlled trial
Location: USA
Language: English
Number of centres: 1
Recruitment period: not reported
Funding source: Procter & Gamble
Participants Participants: 18 to 70 years old. Mean age: 39.1 years
Total number: 20
Inclusion criteria:
  • 16 natural teeth with minimum 7 anterior teeth


Exclusion criteria:
  • previous history of hypersensitivity to test products

  • multiple restorations

  • fixed prosthesis

  • temporomandibular joint disfunction


Number randomised: 19
Method of randomisation: not reported
Method of allocation concealment: not reported
Method of blinding: not reported
Number evaluated: 18
Interventions Total number of intervention groups: 2 (cross‐over)
7.5% sodium hexametaphosphate chewing gum
Placebo
Duration of treatment: 2 weeks with 78 hours washout time
Outcomes Improvement in tooth shade: reduction in stain
ΔL, a*, b* values were recorded. Increase in L and reduction in b indicated whitening
Notes Sample size calculation: not reported
Adverse effects: not reported
Health‐related quality of life: not reported
Key conclusions of the study authors: "Sodium hexametaphosphate delivered from a chewing gum prevents dental stain formation and facilitates stain removal, which leads to a perceptible whitening benefit"
Correspondence required: no
Contact: Dr Aron RB, Procter and Gamble Company, Healthcare Research Center, Manson, Ohio, USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Quote: "Subjects were randomly assigned to one of two treatment groups." However, method was not reported
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk Quote: "Randomised, double‐blinded cross‐over trial." However, method was not reported
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Quote: "Randomised, double‐blinded cross‐over trial." However, method was not reported
Incomplete outcome data (attrition bias) 
 All outcomes Low risk Quote: "1 woman abandoned the study"
Comment: plausible effect size (difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size
Selective reporting (reporting bias) Low risk All outcomes described were reported. Conclusions are in accordance with the results
Other bias Low risk None